Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Intravitreal REGN2176-3 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) (CAPELLA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02418754
Recruitment Status : Terminated (No additional efficacy seen with REGN2176-3 over aflibercept alone)
First Posted : April 16, 2015
Last Update Posted : February 20, 2017
Sponsor:
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Brief Summary:
The primary objective of the study is to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity (BCVA) in patients with neovascular age-related macular degeneration (AMD), compared to intravitreal aflibercept injection (IAI) monotherapy.

Condition or disease Intervention/treatment Phase
Neovascular Age-Related Macular Degeneration Drug: REGN2176-3 Drug: Intravitreal Aflibercept Injection (IAI) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 505 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration
Study Start Date : April 2015
Actual Primary Completion Date : August 2016
Estimated Study Completion Date : June 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group 1
Group 1 will receive REGN2176-3 dosing regimen 1
Drug: REGN2176-3
Experimental: Group 2
Group 2 will receive REGN2176-3 dosing regimen 2
Drug: REGN2176-3
Experimental: Group 3
Group 3 will receive Intravitreal Aflibercept Injection (IAI) monotherapy
Drug: Intravitreal Aflibercept Injection (IAI)
Other Name: Eylea®




Primary Outcome Measures :
  1. Change in Best corrected visual acuity (BCVA) [ Time Frame: Baseline at week 12 ]
    The primary endpoint in the study is the change in BCVA at week 12.


Secondary Outcome Measures :
  1. Change in central retinal lesion thickness as measured by 0ptical coherence tomography (OCT) [ Time Frame: Baseline at week 12 ]
    Change in central retinal lesion thickness from baseline at week 12, as measured by 0ptical coherence tomography (OCT)

  2. Proportion of patients with complete resolution of intraretinal and subretinal fluid as measured by OCT [ Time Frame: Baseline at week 12 ]
    Proportion of patients with complete resolution of intraretinal and subretinal fluid from baseline at week 12, as measured by OCT

  3. Change in choroidal neovascularization (CNV) area as measured by Fluorescein angiography (FA) [ Time Frame: Baseline at week 12 ]
    Change in CNV area from baseline at week 12, as measured by Fluorescein angiography (FA)

  4. Change in lesion size as measured by Optical coherence tomography (OCT) [ Time Frame: Baseline at week 12 ]
    Change in lesion size from baseline at week 12, as measured by Optical coherence tomography (OCT)

  5. Proportion of patients who gain ≥15 letters in BCVA as measured by 4-meter Early Treatment Diabetic Retinopathy Scale (ETDRS) [ Time Frame: Baseline at week 12 ]
    Proportion of patients who gain ≥15 letters in BCVA from baseline at week 12, as measured by 4-meter Early Treatment Diabetic Retinopathy Scale (ETDRS)

  6. Change in subretinal hyperreflectivity material (SHM) as measured by OCT [ Time Frame: Baseline at week 12 ]
    Change in SHM from baseline at week 12, as measured by OCT

  7. Incidence of Treatment-emergent adverse event (TEAEs) [ Time Frame: Baseline to week 12 ]
    Incidence and severity of TEAEs through week 12



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Men or women ≥50 years of age
  2. Active subfoveal CNV secondary to AMD as evidenced by FA in the study eye, as determined by the reading center, including juxtafoveal lesions that affect the fovea
  3. BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye at the screening visit
  4. Provide signed informed consent

Key Exclusion Criteria:

  1. Any prior treatment with anti-VEGF treatment in the study eye
  2. Any prior treatment (ie, systemic or ocular treatment) with PDGF or PDGFR inhibitors
  3. Dense fibrotic scar or atrophy in the study eye involving the center of the fovea
  4. Presence of retinal pigment epithelial tears or rips involving the macula in the study eye
  5. Prior vitrectomy in the study eye
  6. Any history of macular hole of stage 2 and above in the study eye
  7. Any intraocular or periocular surgery within 3 months of day 1 in the study eye, except lid surgery
  8. History of corneal transplant in the study eye
  9. Evidence of diabetic retinopathy or diabetic macular edema in either eye
  10. Positive serum human chorionic gonadotropin/urine pregnancy test at the screening or baseline visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02418754


  Hide Study Locations
Locations
Layout table for location information
United States, Arizona
Phoenix, Arizona, United States
Tucson, Arizona, United States
United States, California
Arcadia, California, United States
Beverly Hills, California, United States
Irvine, California, United States
Mountain View, California, United States
Oceanside, California, United States
Sacramento, California, United States
Santa Ana, California, United States
United States, Colorado
Colorado Springs, Colorado, United States
United States, Florida
Fort Lauderdale, Florida, United States
Fort Myers, Florida, United States
Jacksonville, Florida, United States
Melbourne, Florida, United States
Miami, Florida, United States
Plantation, Florida, United States
Tampa, Florida, United States
Winter Haven, Florida, United States
United States, Georgia
Augusta, Georgia, United States
Marietta, Georgia, United States
United States, Illinois
Chicago, Illinois, United States
Oak Forest, Illinois, United States
Springfield, Illinois, United States
Urbana, Illinois, United States
United States, Iowa
Iowa City, Iowa, United States
United States, Kansas
Shawnee Mission, Kansas, United States
United States, Kentucky
Lexington, Kentucky, United States
Paducah, Kentucky, United States
United States, Maryland
Baltimore, Maryland, United States
Towson, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Michigan
Jackson, Michigan, United States
Southfield, Michigan, United States
United States, Minnesota
Minneapolis, Minnesota, United States
United States, Missouri
Florissant, Missouri, United States
United States, Nebraska
Lincoln, Nebraska, United States
Omaha, Nebraska, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New Jersey
Bloomfield, New Jersey, United States
New Brunswick, New Jersey, United States
United States, New Mexico
Albuquerque, New Mexico, United States
United States, New York
Albany, New York, United States
East Setauket, New York, United States
Great Neck, New York, United States
New York, New York, United States
Orchard Park, New York, United States
Rochester, New York, United States
United States, North Carolina
Asheville, North Carolina, United States
Charlotte, North Carolina, United States
United States, Ohio
Cincinnati, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Oregon
Portland, Oregon, United States
United States, Pennsylvania
Kingston, Pennsylvania, United States
Monroeville, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
United States, South Carolina
Florence, South Carolina, United States
Ladson, South Carolina, United States
West Columbia, South Carolina, United States
United States, South Dakota
Rapid City, South Dakota, United States
United States, Tennessee
Knoxville, Tennessee, United States
Memphis, Tennessee, United States
Nashville, Tennessee, United States
United States, Texas
Abilene, Texas, United States
Austin, Texas, United States
Dallas, Texas, United States
Fort Worth, Texas, United States
Houston, Texas, United States
McAllen, Texas, United States
San Antonio, Texas, United States
The Woodlands, Texas, United States
Willow Park, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
United States, Vermont
Burlington, Vermont, United States
United States, Virginia
Fairfax, Virginia, United States
United States, Washington
Bellevue, Washington, United States
Japan
Akita, Japan
Asahikawa, Japan
Chiyoda-ku, Japan
Fukushima, Japan
Kawasaki, Japan
Matsumoto, Japan
Nagasaki, Japan
Nagoya, Japan
Osaka, Japan
Sponsors and Collaborators
Regeneron Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Clinical Trial Management Regeneron Pharmaceuticals

Layout table for additonal information
Responsible Party: Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02418754     History of Changes
Obsolete Identifiers: NCT02603484
Other Study ID Numbers: R2176-3-AMD-1417
First Posted: April 16, 2015    Key Record Dates
Last Update Posted: February 20, 2017
Last Verified: February 2017

Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases